Literature DB >> 1310542

Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups.

T Janáky1, A Juhász, S Bajusz, V Csernus, G Srkalovic, L Bokser, S Milovanovic, T W Redding, Z Rékási, A Nagy.   

Abstract

In an attempt to produce better cytotoxic analogues, chemotherapeutic antineoplastic radicals including an alkylating nitrogen mustard derivative of D-phenylalanine (D-melphalan), reactive cyclopropane, anthraquinone derivatives [2-(hydroxymethyl)anthraquinone and the anticancer antibiotic doxorubicin], and an antimetabolite (methotrexate) were coupled to suitably modified agonists and antagonists of luteinizing hormone-releasing hormone (LH-RH). Analogues with D-lysine6 and D-ornithine6 or N epsilon-(2,3-diaminopropionyl)-D-lysine and N delta-(2,3-diaminopropionyl)-D-ornithine were used as carriers for one or two cytotoxic moieties. The enhanced biological activities produced by the incorporation of D amino acids into position 6 of the agonistic analogues were further increased by the attachment of hydrophobic cytotoxic groups, resulting in compounds with 10-50 times higher activity than LH-RH. Most of the monosubstituted agonistic analogues showed high affinities for the membrane receptors of human breast cancer cells, while the receptor binding affinities of peptides containing two cytotoxic side chains were lower. Antagonistic carriers [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Trp3,Arg5,D-Lys6,D-Ala10] LH-RH [where Nal(2) is 3-(2-naphthyl)alanine], [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Trp3,Arg5,N epsilon-(2,3-diaminopropionyl)-D-Lys6,D-Ala10]LH-RH, and their D-Pal(3)3 homologs [Pal(3) is 3-(3-pyridyl)alanine] as well as [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Pal(3)3,Tyr5,N epsilon-(2,3-diamino-propionyl)-D-Lys6,D-Ala10]LH-RH were linked to cytotoxic compounds. The hybrid molecules inhibited ovulation in rats at doses of 10 micrograms and suppressed LH release in vitro. The receptor binding of cytotoxic analogues was decreased compared to the precursor peptides, although analogues with 2-(hydroxymethyl)anthraquinone hemiglutarate had high affinities. All of the cytotoxic analogues tested inhibited [3H]thymidine incorporation into DNA in cultures of human breast and prostate cancer cell lines. Some cytotoxic analogues also significantly suppressed the growth of mammary and prostate cancers in vivo in animal models.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1310542      PMCID: PMC48367          DOI: 10.1073/pnas.89.3.972

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

1.  Membrane receptors for peptides in experimental and human pancreatic cancers.

Authors:  M Fekete; A Zalatnai; A M Comaru-Schally; A V Schally
Journal:  Pancreas       Date:  1989       Impact factor: 3.327

2.  Presence of somatomedin receptors on primary human breast and colon carcinomas.

Authors:  M N Pollak; J F Perdue; R G Margolese; K Baer; M Richard
Journal:  Cancer Lett       Date:  1987-12       Impact factor: 8.679

3.  Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer.

Authors:  F Pekonen; S Partanen; T Mäkinen; E M Rutanen
Journal:  Cancer Res       Date:  1988-03-01       Impact factor: 12.701

4.  New analogs of luliberin which inhibit ovulation in the rat.

Authors:  K Channabasavaiah; J M Stewart
Journal:  Biochem Biophys Res Commun       Date:  1979-02-28       Impact factor: 3.575

5.  Hormone-drug conjugates.

Authors:  J M Varga
Journal:  Methods Enzymol       Date:  1985       Impact factor: 1.600

6.  Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer.

Authors:  M Fekete; J L Wittliff; A V Schally
Journal:  J Clin Lab Anal       Date:  1989       Impact factor: 2.352

7.  Highly potent analogues of luteinizing hormone-releasing hormone containing D-phenylalanine nitrogen mustard in position 6.

Authors:  S Bajusz; T Janaky; V J Csernus; L Bokser; M Fekete; G Srkalovic; T W Redding; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

8.  Individual chemosensitivity of in vitro proliferating mammary and ovarian carcinoma cells in comparison to clinical results of chemotherapy.

Authors:  M Albrecht; W E Simon; F Hölzel
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

Review 9.  Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies.

Authors:  A V Schally; G Srkalovic; B Szende; T W Redding; T Janaky; A Juhasz; E Korkut; R Z Cai; K Szepeshazi; S Radulovic
Journal:  J Steroid Biochem Mol Biol       Date:  1990-12-20       Impact factor: 4.292

10.  Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata.

Authors:  G Emons; G S Pahwa; C Brack; R Sturm; F Oberheuser; R Knuppen
Journal:  Eur J Cancer Clin Oncol       Date:  1989-02
View more
  15 in total

1.  Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.

Authors:  A Nagy; A V Schally; P Armatis; K Szepeshazi; G Halmos; M Kovacs; M Zarandi; K Groot; M Miyazaki; A Jungwirth; J Horvath
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  A chemically labeled cytotoxic agent: two-photon fluorophore for optical tracking of cellular pathway in chemotherapy.

Authors:  X Wang; L J Krebs; M Al-Nuri; H E Pudavar; S Ghosal; C Liebow; A A Nagy; A V Schally; P N Prasad
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

3.  Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors.

Authors:  K Szepeshazi; A V Schally; G Halmos; B Szoke; K Groot; A Nagy
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  Investigational Strategies for Detection and Intervention in Early-Stage Pancreatic Cancer. April 24-27, Annapolis, Maryland. Abstracts.

Authors: 
Journal:  Int J Pancreatol       Date:  1994 Oct-Dec

5.  Selective coupling of methotrexate to peptide hormone carriers through a gamma-carboxamide linkage of its glutamic acid moiety: benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate activation in salt coupling.

Authors:  A Nagy; B Szoke; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

6.  Short-chain analogs of luteinizing hormone-releasing hormone containing cytotoxic moieties.

Authors:  T Janáky; A Juhász; Z Rékási; P Serfözö; J Pinski; L Bokser; G Srkalovic; S Milovanovic; T W Redding; G Halmos
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

7.  Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor.

Authors:  S R Milovanovic; S Radulovic; A V Schally
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

8.  Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma.

Authors:  S R Milovanovic; E Monje; K Szepeshazi; S Radulovic; A Schally
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

Review 9.  Gonadotrophin-releasing hormone agonists. A guide to use and selection.

Authors:  M Filicori
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

10.  Probing the GnRH receptor agonist binding site identifies methylated triptorelin as a new anti-proliferative agent.

Authors:  Kevin Morgan; Samuel P Leighton; Robert P Millar
Journal:  J Mol Biochem       Date:  2012-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.